The duration of regorafenib therapy depends on the type of cancer being treated, how the patient responds to the drug and whether side effects are manageable. However, some general guidelines can be provided for the most common indications:

1. Metastatic colorectal cancer (mCRC):

Duration of therapy: Regorafenib is usually given as a daily oral treatment for four weeks, followed by two weeks off, forming a 6-week cycle.

Course of treatment: Treatment with regorafenib is continued until disease progression or intolerable side effects occur. This can vary considerably from patient to patient.

On average, patients can continue therapy for several months as long as the drug is effective and side effects are manageable. In clinical trials, regorafenib was used until disease progression, and many patients continued therapy for 6–12 months.

2. Hepatocellular carcinoma (HCC):
Duration of therapy: Regorafenib for advanced HCC is also given on a 4-week-on, 2-week-off cycle. Treatment continues as long as there is clinical benefit, such as stable disease or response, and the patient tolerates the drug.

Treatment course: As with mCRC, treatment generally continues until there is evidence of disease progression or the patient has significant side effects. In clinical trials, the average duration of treatment with regorafenib in patients with advanced HCC was approximately 4–6 months.

3. Gastrointestinal stromal tumors (GISTs):
Duration of therapy: For GISTs, regorafenib is given continuously until disease progression or unacceptable side effects develop. The duration of treatment depends on how well the cancer responds to treatment.

Treatment course: The average treatment duration can range from several months to more than a year in some cases, depending on the individual response to and tolerance of the drug.

4. Renal cell carcinoma (RCC):
When used in combination with immunotherapy (e.g., nivolumab), regorafenib is generally continued as long as there is clinical benefit and the patient does not experience significant toxicity. The exact duration of therapy in RCC depends on the treatment protocol and the patient's response.

Key points about regorafenib therapy duration:
Continuous treatment: Regorafenib is often given continuously in cycles (4 weeks on, 2 weeks off) for most indications, and patients are usually treated until there is evidence of disease progression or intolerable side effects.
 

Individualized treatment: The duration of treatment is highly individualized. Some patients may remain on regorafenib for several months or even longer if the drug is effective and well tolerated.

Monitoring: During treatment, patients will need to undergo regular monitoring to assess how well the drug is working and check for any adverse effects. This monitoring helps decide whether to continue, adjust, or stop therapy.

It is important for patients on regorafenib therapy to have frequent follow-up visits with their oncologist to assess both the effectiveness of the treatment and the tolerability of the drug.

Website: Regorafenib Price in Philippines